Faeth Therapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $109.70M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 13, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 4, 2026 | Before market open | – | $-2.84 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 15, 2026 | Before market open | – | $-131.45 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 30, 2026 | Before market open | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 14, 2025 | Before market open | – | $-3.62 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 5, 2025 | Before market open | – | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 6, 2025 | Before market open | – | $-0.27 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 28, 2025 | Before market open | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 14, 2024 | Before market open | – | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 6, 2024 | Before market open | – | $-0.28 | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 9, 2024 | Before market open | – | $-0.32 | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 28, 2024 | Before market open | – | – | – |
Press releases
Announcements Faeth Therapeutics filed with the SEC
Faeth Therapeutics Reports Second Quarter 2026 Financial Results and Operational Updates
Results of operations · EX-99.1 to Form 8-K
Sensei Biotherapeutics Announces Name Change to Faeth Therapeutics, Focused on Advancing PIKTOR, an Oral Therapy Targeting One of the Most
Agreement terminated · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
UNAUDITED PRO FORMA CONDENSED FINANCIAL INFORMATION
Other events · EX-99.1 to Form 8-K
Sensei Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Sensei Biotherapeutics Reports Full Year 2025 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Sensei Biotherapeutics Announces Acquisition of Faeth Therapeutics and $200 Million Concurrent Private Placement
Material agreement · Acquisition or disposition completed · Unregistered share sale · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
–– Disclaimers The information in this Presentation has been
Material agreement · Acquisition or disposition completed · Unregistered share sale · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · EX-99.2 to Form 8-K
Sensei Biotherapeutics Reports Third Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Sensei Biotherapeutics Announces Initiation of Strategic Review to Maximize Shareholder Value
Regulation FD disclosure · EX-99.1 to Form 8-K
Sensei Biotherapeutics Reports New Clinical Results Highlighting Durable Progression Free Survival Data for Solnerstotug in PD-(L)1 Resistant Tumors at the ESMO Congress 2025
Regulation FD disclosure · EX-99.1 to Form 8-K
Therapeutics October 2025 Exhibit 99.2
Regulation FD disclosure · EX-99.2 to Form 8-K
Sensei Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Sensei Biotherapeutics Reports First Quarter 2025 Financial Results and Updates on Clinical Progress
Results of operations · EX-99.1 to Form 8-K
Sensei Biotherapeutics Reports Full Year 2024 Financial Results and Update on Clinical Progress
Results of operations · EX-99.1 to Form 8-K
Sensei Biotherapeutics Reports Favorable Preliminary Dose Expansion Data for Solnerstotug in PD-(L)1
Regulation FD disclosure · EX-99.1 to Form 8-K
Immuno-oncology March 2025 Exhibit 99.2
Regulation FD disclosure · EX-99.2 to Form 8-K
Sensei Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Results of operations · EX-99.1 to Form 8-K
Sensei Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
Results of operations · EX-99.1 to Form 8-K
Immuno-oncology Corporate Deck | June 2024 Exhibit 99.1
Regulation FD disclosure · EX-99.1 to Form 8-K
Sensei Biotherapeutics Presents Promising Clinical Data from Phase 1 Dose Escalation Study of
Regulation FD disclosure · EX-99.1 to Form 8-K
Sensei Biotherapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
Results of operations · EX-99.1 to Form 8-K
Sensei Biotherapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights
Results of operations · EX-99.1 to Form 8-K
Immuno-oncology Corporate Deck | January 2024 Exhibit 99.1
Regulation FD disclosure · EX-99.1 to Form 8-K
Sensei Biotherapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights
Results of operations · EX-99.1 to Form 8-K
Sensei Biotherapeutics Reports Favorable Clinical Data for SNS-101 at 2023 SITC Annual Meeting
Regulation FD disclosure · EX-99.1 to Form 8-K
Immuno-oncology NOVEMBER 2023 | Nasdaq: SNSE Exhibit 99.2
Regulation FD disclosure · EX-99.2 to Form 8-K
Sensei Biotherapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
Results of operations · EX-99.1 to Form 8-K
June 27, 2023 A New Vista for Cancer
Regulation FD disclosure · EX-99.1 to Form 8-K
Sensei Biotherapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights
Results of operations · EX-99.1 to Form 8-K
Immuno-oncology APRIL 2023 | Nasdaq: SNSE Exhibit 99.1
Regulation FD disclosure · EX-99.1 to Form 8-K
Sensei Biotherapeutics Reports Full Year 2022 Financial Results and Recent Business Highlights
Results of operations · EX-99.1 to Form 8-K
Immuno-oncology MARCH 2023 | Nasdaq: SNSE Exhibit 99.1
Regulation FD disclosure · EX-99.1 to Form 8-K
Sensei Biotherapeutics Adopts Stockholder Rights Agreement
Material agreement · Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
Sensei Biotherapeutics Signs Cooperative Research and Development Agreement (CRADA) with the National
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Sensei Biotherapeutics Provides Update on Strategic Priorities
Exit or restructuring costs · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Sensei Biotherapeutics Presents Preclinical Data at the
Regulation FD disclosure · EX-99.1 to Form 8-K
Sensei Biotherapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Immuno-oncology NOVEMBER 2022 | Nasdaq: SNSE Exhibit 99.2
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Sensei Biotherapeutics Presents Preclinical Data for SNS-101, a
Regulation FD disclosure · EX-99.1 to Form 8-K
Sensei Biotherapeutics Announces New Preclinical Data Demonstrating
Regulation FD disclosure · EX-99.1 to Form 8-K